Invivyd Inc (NASDAQ:IVVD) has dosed the first participants in its LIBERTY Phase 3 trial, a study testing the company's monoclonal antibody VYD2311 for the prevention of COVID-19 against and alongside an mRNA vaccine.
The randomized, double-blind trial is evaluating the safety, tolerability and immune response of VYD2311 on its own, an mRNA COVID-19 vaccine on its own, and VYD2311 given together with a COVID-19 vaccine in healthy adults, the New Haven, Connecticut-based company said. Invivyd described VYD2311 as a vaccine-alternative monoclonal antibody candidate, positioning it as an option for people seeking protection without a conventional vaccine.
Depending on enrollment, Invivyd expects topline data from LIBERTY in the third quarter of 2026. The company said those results would accompany anticipated data from its pivotal DECLARATION trial, lining up two readouts on VYD2311 in the same period.
Dosing the first participants moves VYD2311 into late-stage testing and sets a near-term catalyst for the program. Monoclonal antibodies for COVID-19 prevention target people, such as the immunocompromised, who may not respond well to vaccines. The LIBERTY design, which tests the antibody both alone and with a vaccine, is structured to show how VYD2311 performs in each setting.
Invivyd is developing VYD2311 as part of a focus on antibody-based protection against COVID-19.